RECOMBINANT IL-5 ANTAGONIST USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDER

• Main Authors: AMES ROBERT S, APPELBAUM EDWARD ROBERT, THEISEN TIMOTHY WAYNE, CHAIKEN IRWIN M, HOLMES STEPHEN DUDLEY, COOK RICHARD M, MCMILLAN LYNETTE JANE, GROSS MITCHELL STUART
• Format: Patent
• Language: English
• Published: 14.02.2008
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide a high affinity IL-5 antagonist that is a high affinity antagonist such as a neutralizing monoclonal antibody against human interleukin 5 and inhibits differentiation and proliferation of eosinophils and inhibits inflammation caused by eosinophils. SOLUTION: Disclosed are rodent neutralizing monoclonal antibodies specific for human interleukin-5 having a binding affinity characterized by a dissociation constant equal to or less than about 3.5×10-11M and containing the heavy chain and light chain of a variable complementarity determining region (CDR). COPYRIGHT: (C)2008,JPO&INPIT